Parkinson's disease is increasingly framed not only as a disorder of dopamine loss but as one of failing cellular energy metabolism. A growing body of preclinical and early clinical work asks whether declining levels of nicotinamide adenine dinucleotide (NAD+) are a driver, a consequence, or a measurable marker of that energetic failure — a question researchers are still working to resolve.

NAD+ and the energy economy of the neuron

Nicotinamide adenine dinucleotide is one of the most heavily used small molecules in cell biology. In its oxidized (NAD+) and reduced (NADH) forms it shuttles electrons through glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation, making it indispensable to the mitochondrial machinery that generates adenosine triphosphate (ATP).⁷ Neurons are among the most energy-hungry cells in the body: they maintain steep ion gradients, recycle neurotransmitters, and support long axonal projections, all of which depend on a continuous ATP supply. Because these cells have limited glycolytic reserve, they lean heavily on mitochondrial respiration, and therefore on an adequate NAD+/NADH pool.³

Beyond its redox role, NAD+ is consumed as a substrate by three families of enzymes that regulate the cellular stress response: the sirtuins (NAD+-dependent deacylases that influence mitochondrial biogenesis and inflammation), the poly(ADP-ribose) polymerases (PARPs, activated by DNA damage), and the cyclic ADP-ribose synthases such as CD38.³ Each of these reactions cleaves NAD+, meaning that signaling demand and metabolic demand draw on the same finite pool. In experimental systems, sustained activation of PARPs or CD38 can lower NAD+ availability enough to impair sirtuin-driven mitochondrial maintenance.⁹

This dual accounting — NAD+ as both an energy currency and a signaling substrate — is central to why the cofactor attracts interest in neurodegeneration research. Studies in cultured neurons and rodent tissue report that when NAD+ falls, mitochondrial respiration, DNA repair capacity, and mitophagy (the clearance of damaged mitochondria) can all decline together.⁴⁸

The autophagy–NAD axis

One thread of recent work connects NAD+ metabolism to autophagy and mitophagy. In model organisms, NAD+ repletion has been reported to stimulate the removal of dysfunctional mitochondria, a quality-control process that becomes less efficient with age.⁸ Fang and colleagues showed in Alzheimer's disease models that boosting mitophagy reduced pathological protein burden and improved behavioral readouts in the animals studied, a mechanism proposed to overlap with NAD+-dependent pathways.⁴ Because impaired mitochondrial clearance is also a feature of Parkinson's disease models, this axis is one reason NAD+ biology and Parkinson's research increasingly intersect.

Why NAD+ pools fall in aging and Parkinson's models

Aging is the single largest risk factor for Parkinson's disease, and aging itself is accompanied by a measurable decline in tissue NAD+ across many organs, including the brain, in the model systems that have been examined.⁵ Reviews of the aging literature attribute this to a shifting balance between NAD+ synthesis and consumption rather than to a single lesion.⁶ Three interacting mechanisms are commonly described.

1. Increased NAD+ consumption

Chronic low-grade inflammation and accumulating DNA damage raise the activity of NAD+-consuming enzymes. CD38, which rises with age in many tissues, and PARP1, activated by oxidative DNA lesions, both draw down the shared pool faster than it can be replenished.⁹ In neurodegeneration models this creates a feed-forward loop in which damage begets NAD+ loss, which in turn limits the repair capacity that would otherwise contain the damage.³

2. Impaired mitochondrial reoxidation of NADH

Parkinson's disease models are characterized by complex I dysfunction in the mitochondrial electron transport chain. When complex I is impaired, NADH is not efficiently reoxidized back to NAD+, distorting the NAD+/NADH ratio and stalling downstream ATP synthesis.⁷ Genetic forms of the disease implicate the PINK1 and Parkin proteins, which govern the labeling and clearance of damaged mitochondria; loss of their function is associated with the accumulation of respiration-deficient organelles in experimental systems.⁶

3. Constrained biosynthesis and salvage

Cells regenerate NAD+ mainly through a salvage pathway that recycles nicotinamide, with contributions from dietary precursors such as nicotinamide riboside and nicotinic acid. Stress conditions can bottleneck the rate-limiting salvage enzyme NAMPT, reducing the cell's ability to rebuild NAD+.¹⁰ Work on injured axons has shown that manipulating this pathway — for example by supplying the precursor nicotinic acid riboside or modulating NAMPT — changes the tempo of Wallerian (axonal) degeneration in mammalian nerve models, underscoring how tightly axon survival is coupled to local NAD+ supply.¹⁰

Together these mechanisms describe a plausible route by which the aging, stressed neuron accumulates an NAD+ deficit. What they do not yet establish is the direction of causation in the human disease — a distinction the next section examines.

What the evidence actually links to progression

It is important to separate three claims that are easily conflated: that NAD+ declines in aging tissue, that Parkinson's disease models show additional NAD+-pathway stress, and that this decline drives clinical progression in patients. The first is well supported across species.⁵ The second is supported by cell and rodent data.¹⁶ The third — a causal link to progression in people — remains an open research question rather than a settled fact.

Comprehensive reviews of NAD+ in brain aging conclude that low NAD+ is a shared feature across several neurodegenerative conditions and a candidate contributor to their pathology, while stopping short of asserting causation in humans.³ Analyses focused specifically on Parkinson's disease frame mitochondrial and metabolic decline as one strand of a multifactorial process that also includes protein aggregation, neuroinflammation, and impaired proteostasis.⁶ In other words, NAD+ deficiency is best read as one node in a network rather than a solitary cause.

Restoring NAD+: what precursor trials have measured

The most direct human data come from small randomized trials of nicotinamide riboside, an oral NAD+ precursor, in people with Parkinson's disease. The NADPARK study, a randomized phase I trial, reported that a 30-day course of nicotinamide riboside raised NAD+ levels in the brain — measured non-invasively — and in blood cells, and it detected changes in metabolic and inflammatory markers in a subset of participants.¹ The authors were explicit that the trial was designed to establish target engagement and tolerability, not to demonstrate a change in the course of the disease.

A follow-on study, NR-SAFE, was a randomized double-blind trial that tested a substantially higher daily dose over several weeks and monitored tolerability and adverse events in a Parkinson's population.² These trials establish that the pathway can be pharmacologically engaged in humans and that cerebral NAD+ is measurable before and after intervention. They do not, individually or together, establish that NAD+ precursors alter Parkinson's disease progression; larger and longer trials with clinical endpoints would be required for that conclusion.²

Reviews of translational NAD+ research reach a similar posture: the biology is compelling and the early human signals justify further study, but the field is at the stage of mechanism and feasibility rather than confirmed clinical outcomes.⁹ For researchers, this is precisely the space where well-characterized reference material matters, whether the compound of interest is NAD+ itself or a mitochondrial-derived peptide such as MOTS-c studied in parallel metabolic-signaling contexts.

Measuring NAD+ as a research readout

A practical reason NAD+ has become attractive in Parkinson's research is that it can be quantified. Phosphorus-31 magnetic resonance spectroscopy (³¹P-MRS) allows non-invasive estimation of NAD+ and high-energy phosphate metabolites in living tissue, and it was one of the techniques used to confirm cerebral target engagement in the NADPARK cohort.¹ In parallel, NAD+ and its metabolites can be assayed in blood cells and biopsy tissue by mass spectrometry, and NAD+/NADH ratios can be tracked in cultured cells.

These readouts let investigators ask focused mechanistic questions: does a given intervention raise the NAD+ pool, in which compartment, and for how long, and do downstream markers of mitochondrial function or inflammation move in step? Because the measurements are quantitative and repeatable, NAD+ functions less as a proven biomarker of disease severity and more as a tractable variable for probing the metabolic hypotheses discussed above.³ Reproducibility here depends on consistent, well-defined reference compounds, since NAD+ is chemically labile and sensitive to handling.

Open questions and evidence limits

Several questions remain genuinely unsettled. It is not established whether the NAD+ decline seen in Parkinson's models precedes neuronal loss or follows it; longitudinal human data are sparse. It is unclear which cellular compartment — cytosolic, mitochondrial, or nuclear — is most relevant to disease, since these pools are regulated semi-independently.⁵ The relative contribution of increased consumption (via CD38 and PARPs) versus impaired synthesis is still being weighed.⁹ And the durability of any metabolic change from precursor supplementation, along with its relationship to clinical measures, is not yet defined by adequately powered trials.²

What can be said is narrow but real: NAD+ sits at the intersection of energy metabolism, DNA repair, and mitochondrial quality control, all of which are disturbed in Parkinson's disease models; the pathway is measurable and pharmacologically accessible in humans; and early trials have engaged it without establishing therapeutic effect. That is a foundation for continued laboratory investigation, not a basis for clinical claims.

Research-grade NAD+ at Qovigen

Rigorous work on the NAD+–Parkinson's question depends on material of known identity and purity, because NAD+ degrades readily and small handling differences can confound sensitive assays. Qovigen supplies NAD+ (500 mg) as a research-grade, batch-tested reference compound intended for in-vitro and preclinical study, alongside complementary items such as bacteriostatic water for reconstitution in the laboratory. These materials are offered strictly for research use and are not intended for human or veterinary administration.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.